ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,464.62
      -0.16%
      US Tech 100
      19,220.00
      -0.20%
      Dow Jones
      39,150.33
      0.04%
      Brent Oil
      84.39
      0.00%
      Bitcoin
      64,071.42
      -0.27%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Altimmune Inc (ALT) Quote

      Altimmune Inc

      Altimmune Inc (ALT)

      Analytica Limited
      Altitude Group Plc
      Alturas Minerals Corp
      6.41
      0.47
      (7.91%)
      Closed June 23 4:00PM
      Delayed by 15 minutes
      6.535
      0.125
      (1.95%)
      After Hours: 7:55PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      6.535
      Bid
      5.00
      Ask
      7.48
      Volume
      11,137,556
      5.99 Day's Range 6.755
      2.09 52 Week Range 14.84
      Market Cap
      452.356M
      Previous Close
      5.94
      Open
      6.00
      Last Trade
      1
      @
      6.54
      Last Trade Time
      Financial Volume
      $ 70,141,057
      VWAP
      6.2977
      Average Volume (3m)
      2,857,780
      Shares Outstanding
      70,902,191
      Dividend Yield
      -
      PE Ratio
      -5.11
      Earnings Per Share (EPS)
      -1.25
      Revenue
      426k
      Net Profit
      -88.45M

      About Altimmune Inc

      Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.altimmune.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Altimmune Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALT. The last closing price for Altimmune was $5.94. Over the last year, Altimmune shares have traded in a share price range of $ 2.09 to $ 14.84.

      Altimmune currently has 70,902,191 shares outstanding. The market capitalization of Altimmune is $452.36 million. Altimmune has a price to earnings ratio (PE ratio) of -5.11.

      ALT Latest News

      More News

      Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Associationā€™s 84th Scientific Sessions

      GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical...

      2 hours ago
      GlobeNewswire Inc.

      Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Associationā€™s 84th Annual Scientific Sessions

      GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its...

      23 hours ago
      GlobeNewswire Inc.

      Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways

      GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyā€™s management team will...

      June 20 2024
      GlobeNewswire Inc.

      Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT

      Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT PR Newswire NEW YORK, June 20, 2024 NEW YORK, June 20...

      June 20 2024
      PR Newswire (US)

      Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Associationā€™s Scientific Sessions

      GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an...

      June 18 2024
      GlobeNewswire Inc.

      The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT

      The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT PR Newswire NEW YORK, June 17, 2024 NEW YORK, June 17, 2024 /PRNewswire/...

      June 17 2024
      PR Newswire (US)

      The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT

      The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT PR Newswire NEW YORK, June 10, 2024 NEW YORK, June 10, 2024 /PRNewswire/...

      June 10 2024
      PR Newswire (US)

      Altimmune Presents Data at EASL International Liver Congressā„¢ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

      Follow-on analyses of non-invasive tests from Phase 1 trials in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) suggest the potential for meaningful histologic improvements with...

      June 05 2024
      GlobeNewswire Inc.

      Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ALT

      Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ALT PR Newswire NEW YORK, June 5, 2024 NEW YORK, June 5, 2024 /PRNewswire/...

      June 05 2024
      PR Newswire (US)

      Altimmune to Participate at Two Upcoming Investor Conferences

      GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyā€™s management team will...

      May 29 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.0450.6933744221886.496.7555.6428744095.95843325CS
      4-0.875-11.80836707157.417.93995.6424804206.64444155CS
      12-3.715-36.24390243910.2511.015.6428577807.51271195CS
      26-1.705-20.69174757288.2414.845.6449261189.7403206CS
      522.48561.35802469144.0514.842.0947602787.40908232CS
      156-9.275-58.665401644515.8123.492.0926125848.6195014CS
      2604.225182.90043292.3135.11.45221797910.05449429CS

      Market Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AREBAmerican Rebel Holdings Inc
      $ 0.76
      (152.49%)
      		371.46M
      SHCRSharecare Inc
      $ 1.365
      (76.27%)
      		56.33M
      NXLNexalin Technologies Inc
      $ 1.7499
      (59.08%)
      		57.58M
      FUFUBitFuFu Inc
      $ 6.1209
      (56.95%)
      		2.5M
      SPECSpectaire Holdings Inc
      $ 0.50
      (47.06%)
      		65.27M
      FLFVFeutune Light Acquisition Corporation
      $ 2.5502
      (-69.75%)
      		862.38k
      FLFVUFeutune Light Acquisition Corporation
      $ 2.75
      (-66.83%)
      		16.5k
      RWODRedwoods Acquisition Corporation
      $ 2.34
      (-60.34%)
      		155.96k
      KAVLKaival Brands Innovations Group Inc
      $ 1.23
      (-57.14%)
      		4.92M
      RWODURedwoods Acquisition Corporation
      $ 3.24
      (-56.28%)
      		1.47k
      NVDANVIDIA Corporation
      $ 126.57
      (-3.22%)
      		658.13M
      AREBAmerican Rebel Holdings Inc
      $ 0.76
      (152.49%)
      		371.46M
      SIRISirius XM Holdings Inc
      $ 2.94
      (1.38%)
      		330.66M
      AAPLApple Inc
      $ 207.49
      (-1.04%)
      		246.38M
      NKLANikola Corporation
      $ 0.3466
      (5.16%)
      		193.36M

      ALT Discussion

      View Posts
      Mark102 Mark102 2 days ago
      Last chance next week above 20
      šŸ‘ļø0
      Mark102 Mark102 5 days ago
      It's being shorted by its competitors not tutes. . An advisor from Lilly is making the presentations of pemvi data this weekend.its what you know not what some want you to believe.
      šŸ‘ļø0
      brfv11 brfv11 1 week ago
      Not a chance at 60. Shorts are playing this one perfectly. Investors are just not interested in ALT. Good luck.
      šŸ‘ļø0
      Mark102 Mark102 1 week ago
      Shorts looking weak and vulnerable today any trading room with the funds could squeeze this to 60 easy
      šŸ‘ļø0
      Mark102 Mark102 2 weeks ago
      Goldman Sachs been short stacking here for months and they are hosting the fireside tomorrow. I'm loading up today
      šŸ‘ļø0
      brfv11 brfv11 2 weeks ago
      Time to admit shorty got this one right! This one is going all the way down.
      Merger/ buyout what a joke.
      šŸ‘ļø0
      akamaii akamaii 3 weeks ago
      This Wednesday we hope data rules. Give us data 📈
      šŸ‘ļø0
      akamaii akamaii 2 months ago
      Going long for a year 75 target or 50 plus
      šŸ‘ļø0
      Mt. Blanc Mt. Blanc 2 months ago
      So much for my ALT prediction.

      The stock slipped to $7 and may be cratering more since it's getting no love.

      Maybe ALT is a $5 stock or lower if buyers aren't interested.

      mb
      šŸ‘ļø0
      Mt. Blanc Mt. Blanc 3 months ago
      Radar. ALT $11- $12

      Getting picked up.

      mb
      šŸ‘ļø0
      Monksdream Monksdream 3 months ago
      ALT over $10
      Next day settlement begins 5/28 per SEC mandate
      šŸ‘ļø0
      Monksdream Monksdream 3 months ago
      ALT 10Q due 3/27
      Next day settlement begins 5/28
      šŸ‘ļø0
      saigai saigai 3 months ago
      patiently waiting.. for sure something in the way of news is right there and it can only be a plus.. i want the buyout.. let say 4 billion.. 80 bucks a share..gl
      šŸ‘ļø0
      Mark102 Mark102 3 months ago
      Buyout? Partnership? In less than 9 trading days we will find out.
      šŸ‘ļø0
      Mark102 Mark102 3 months ago
      BUCKLE UP. going to break 15 soon
      šŸ‘ļø0
      saigai saigai 4 months ago
      a good read
      https://www.rcplondon.ac.uk/news/world-obesity-day-let-s-talk-about-drugs
      šŸ‘ļø0
      saigai saigai 4 months ago
      slow and steady is healthy as the data goes as well.. fast weight loss is never good and the deeper dive into the data im sure will find that Alt has a wider profile a safer profile as it relates to muscle loss and bone density. time will tell...in any case the real value here is the undiscovered uses.. wide profile more mkts...long and strong ...
      šŸ‘ļø0
      Mt. Blanc Mt. Blanc 4 months ago
      ALT @ $12?

      Interesting

      mb
      šŸ‘ļø0
      saigai saigai 4 months ago
      institutional ownership from nasdaq site
      https://www.nasdaq.com/market-activity/stocks/alt/institutional-holdings
      šŸ‘ļø0
      saigai saigai 4 months ago
      big volume wrong direction for now
      šŸ‘ļø0
      saigai saigai 4 months ago
      a good read
      https://finance.yahoo.com/news/weight-loss-drugs-patients-lose-134837816.html
      šŸ‘ļø0
      saigai saigai 5 months ago
      and a few more...
      šŸ‘ļø0
      saigai saigai 5 months ago
      you wont be able to chase this..you either in before the news or outside looking in.. patience of a saint..
      šŸ‘ļø0
      saigai saigai 5 months ago
      driving me nutz but i wont sell this until !!!
      šŸ‘ļø0
      murocman murocman 5 months ago
      Post from another board relevant to ALT:

      GLP-1 drugs will_be supply-constrained for_a_few_years, according to the NVO and LLY webcasts at JPM. All in-house and CMO capacity suitable for manufacturing injected GLP-1 drugs is already in service. Moreover, the eventual uptake of oral GLP-1 drugs will not ease the manufacturing bottleneck as much as people might think because the low bioavailability of the oral agents requires large amounts of API.
      šŸ‘ļø0
      AGORDON AGORDON 5 months ago
      Altimmune, Inc.
      (Nasdaq - ALT) $12/share
      Market cap = $644M
      Cash = $140M
      Cash Burn rate = ($76)/Y
      Catalysts:
      Pemvidutide - Weight loss drug. Peptide based GLP-1/Glucagon dual receptor agonist. Phase 2 results were respectable. At 48 weeks, for 2.4mg (high dose), weight loss of -15.6% (on the low end of the expected 15-20%)., but comparable to Mounjaro. The TRAEs appear to be less than Mounjaro's. The drug did reduce triglycerides.
      HepTCell - an immunotherapeutic for Chronic Hepatitis B. In Phase 2 trials. Next read out could be in April, 2024.
      šŸ‘ļø0
      Mark102 Mark102 5 months ago
      I was wrong ALT is attending the JPM Let's get this deal done.
      šŸ‘ļø0
      saigai saigai 5 months ago
      thanks a lot.. im on a new computer.. id rather have oral surgery than learn a new computer
      šŸ‘ļø0
      Mark102 Mark102 6 months ago
      Data is in check Twitter. Weight loss is a 100 billion market. The results on the liver data show a 100 % reduction of fat at the highest dose. That's a 40 billion market.
      Now why is ALT not attending the JPM conference this week? Stay tuned
      šŸ‘ļø0
      saigai saigai 6 months ago
      im hanging around bewteen the two potential mkts for their drug its too crazy to even think out loud lets see what the data says.. if its good or really good. all hell will break out
      šŸ‘ļø0
      Mark102 Mark102 6 months ago
      Float is locked, tutes trying to shake few out but this is a done deal IMO
      šŸ‘ļø0
      saigai saigai 6 months ago
      this is a powder keg...
      šŸ‘ļø0
      saigai saigai 6 months ago
      i believe if they wanted to they could have closed a deal by now but they wait till after the new data.. i wonder why.. there is no way for this to go but way up from here..glta
      šŸ‘ļø0
      Mark102 Mark102 6 months ago
      Been Holding since 6. Buyout or partnership is imminent.
      šŸ‘ļø0
      1hot toddy 1hot toddy 6 months ago
      HUGE BUYS NOW 10K BUY $100K BUY $$$$$$$$$$$$$$$$$$
      šŸ‘ļø0
      Bud-Wiser Bud-Wiser 6 months ago
      Nice comeback today -Iā€™m back in
      šŸ‘ļø0
      1hot toddy 1hot toddy 6 months ago
      WOOOOOOOOOOOW 10K AND 9100 SHARE BUYS 2-$100,000 BUYS $$$$$$$$$$$$$$$$$$$$$$$$$$$$$
      BABY MONSTER HERE
      šŸ‘ļø0
      eyeownu eyeownu 6 months ago
      got dammmmmmmmmmm. oprah must be buying out the company
      šŸ‘ļø0
      1hot toddy 1hot toddy 6 months ago
      WOOOOOOW 10,000 SHARE BUY $110,000 BUY $$$$$$$$$$$$$$$$
      MONSTER WEIGHT LOSS CO HERE
      šŸ‘ļø0
      Mark102 Mark102 6 months ago
      Next Gap to 19 to fill. PT 60 to 100 on a buyout
      šŸ‘ļø0
      1hot toddy 1hot toddy 6 months ago
      WOOOOOOOOOOOW 21000 SHARE BUY OVER $150,000 BUY . KILLER WEIGHT LOSS HERE $$$$$$$$$$$
      šŸ‘ļø0
      eyeownu eyeownu 6 months ago
      rallys over IMO. end of year.. could be wrong tho!
      šŸ‘ļø0
      1hot toddy 1hot toddy 6 months ago
      WOOOOOOOOOOW 11000 SHARE BUY $90000 BUY WEIGHT LOSS RESULTS GREAT $$$$$
      šŸ‘ļø0
      1hot toddy 1hot toddy 6 months ago
      HUGE BUYS 8000 SHARES PLUS BUNCH OF 4000 SHARE BUYS $$$$$$$$$
      šŸ‘ļø0
      1hot toddy 1hot toddy 6 months ago
      WOOOOOOOW 8800 SHARE BUY $60000 BUY $$$$$$$$$4
      šŸ‘ļø0
      saigai saigai 6 months ago
      volume still there
      šŸ‘ļø0
      1hot toddy 1hot toddy 6 months ago
      25000 share buy plus 10k buy $$$$$$$$$$$$$$
      šŸ‘ļø0
      saigai saigai 6 months ago
      what a day tomorrow even better
      šŸ‘ļø0
      1hot toddy 1hot toddy 6 months ago
      you were smart to add yesterday on big down day. y wait till today on up day to add??? i added more now
      šŸ‘ļø0
      saigai saigai 6 months ago
      buena suerte to all
      šŸ‘ļø0

      Your Recent History

      NASDAQ
      ALT
      Altimmune
      BIT
      P1YFS2
      NLBNPIT1YFS2 20991231 48...
      TG
      IPT
      International Petroleum
      NASDAQ
      AAZQSXX
      Bofa Finance Llc Issuer ...
      Delayed Upgrade Clock